Pharmaceuticals, Biotechnology and Life Sciences
Camurus said Monday that the United States District Court for the District of Columbia granted Braeburn’s motion for summary judgement, vacating the U.S. Food and Drug Administration’s (FDA) decision to block final market approval of Brixadi Monthly.
Designation Granted for Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment KENILWORTH, N.J.…
MedPharm Ltd, a leader in topical and transdermal drug delivery, has expanded its relationship with the NASDAQ listed biopharmaceutical company Novan Inc.
Qu Biologics’s first randomized-placebo controlled trial (RCT) resulst, for moderate-to-severe Crohn’s disease (CD) was accepted for publication in Frontiers in Medicine, an open-access peer-reviewed medical journal, as it showed that clinical symptoms of CD can be improved with an immunomodulatory treatment that functions to activate instead of suppress the immune system.
New research from the FH Foundation highlights that individuals at high risk for cardiovascular events, including those with familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD), experienced more heart attacks, strokes and other cardiovascular events when they were unable to obtain their prescribed PCSK9 inhibitor (PCSK9i), a cholesterol-lowering treatment.
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…
SEATTLE–(BUSINESS WIRE)–LifeSpan BioSciences, Inc. (LSBio™), the industry leader in molecular pathology, today announced the first release of its PathPlus™ series…
Sinomed has completed enrollment in the PIONEER III randomized, controlled clinical trial testing the BuMA Supreme DES and support U.S. and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.
The FDA has granted first approvals for the generic versions of Lyrica to Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, Dr. Reddy’s Laboratories, InvaGen Pharmaceuticals, MSN Laboratories Ltd., Rising Pharmaceuticals, Inc., Sciegen Pharmaceuticals Inc., and Teva Pharmaceuticals.
Week 96 data from the BRIGHTE study of first-in-class fostemsavir continue to show improvement in virologic suppression and immunologic response…